Literature DB >> 19656558

Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial.

Corine M Koopmans1, Denise Bijlenga2, Henk Groen3, Sylvia Mc Vijgen2, Jan G Aarnoudse3, Dick J Bekedam4, Paul P van den Berg3, Karin de Boer5, Jan M Burggraaff6, Kitty Wm Bloemenkamp7, Addy P Drogtrop8, Arie Franx9, Christianne Jm de Groot10, Anjoke Jm Huisjes11, Anneke Kwee12, Aren J van Loon13, Annemiek Lub14, Dimitri Nm Papatsonis15, Joris Am van der Post2, Frans Jme Roumen16, Hubertina Cj Scheepers17, Christine Willekes18, Ben Wj Mol19, Maria G van Pampus3.   

Abstract

BACKGROUND: Robust evidence to direct management of pregnant women with mild hypertensive disease at term is scarce. We investigated whether induction of labour in women with a singleton pregnancy complicated by gestational hypertension or mild pre-eclampsia reduces severe maternal morbidity.
METHODS: We undertook a multicentre, parallel, open-label randomised controlled trial in six academic and 32 non-academic hospitals in the Netherlands between October, 2005, and March, 2008. We enrolled patients with a singleton pregnancy at 36-41 weeks' gestation, and who had gestational hypertension or mild pre-eclampsia. Participants were randomly allocated in a 1:1 ratio by block randomisation with a web-based application system to receive either induction of labour or expectant monitoring. Masking of intervention allocation was not possible. The primary outcome was a composite measure of poor maternal outcome--maternal mortality, maternal morbidity (eclampsia, HELLP syndrome, pulmonary oedema, thromboembolic disease, and placental abruption), progression to severe hypertension or proteinuria, and major post-partum haemorrhage (>1000 mL blood loss). Analysis was by intention to treat and treatment effect is presented as relative risk. This study is registered, number ISRCTN08132825.
FINDINGS: 756 patients were allocated to receive induction of labour (n=377 patients) or expectant monitoring (n=379). 397 patients refused randomisation but authorised use of their medical records. Of women who were randomised, 117 (31%) allocated to induction of labour developed poor maternal outcome compared with 166 (44%) allocated to expectant monitoring (relative risk 0.71, 95% CI 0.59-0.86, p<0.0001). No cases of maternal or neonatal death or eclampsia were recorded.
INTERPRETATION: Induction of labour is associated with improved maternal outcome and should be advised for women with mild hypertensive disease beyond 37 weeks' gestation. FUNDING: ZonMw.

Entities:  

Mesh:

Year:  2009        PMID: 19656558     DOI: 10.1016/S0140-6736(09)60736-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  116 in total

1.  Risk Factors for Preeclampsia in a High-Risk Cohort of Women Served by a Nursing-based Home Visiting Program.

Authors:  Candace Tannis; Rachel Fletcher-Slater; Inessa Lopez; Alexandrah Gichingiri; Mario Cassara; Susanne Lachapelle; Elizabeth Garland
Journal:  Int Public Health J       Date:  2018-10-01

2.  Influence of Preeclampsia on Induction of Labor at Term: A Cohort Study.

Authors:  Jutta Pretscher; Christel Weiss; Ulf Dammer; Florian Stumpfe; Florian Faschingbauer; Matthias W Beckmann; Sven Kehl
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

3.  Induction and cost.

Authors:  Athol Kent
Journal:  Rev Obstet Gynecol       Date:  2011

4.  Expectant or outpatient management of preeclampsia before 34 weeks: safe for mother but associated with increased stillbirth risk.

Authors:  Jing Fu; Chunfang Li; Wenli Gou; Arier Lee; Xuelan Li; Qi Chen
Journal:  J Hum Hypertens       Date:  2019-02-11       Impact factor: 3.012

5.  Nonmedically indicated induction vs expectant treatment in term nulliparous women.

Authors:  Jennifer L Bailit; William Grobman; Yuan Zhao; Ronald J Wapner; Uma M Reddy; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Alan T Tita; George Saade; Yoram Sorokin; Dwight J Rouse; Sean C Blackwell; Jorge E Tolosa; J Peter VanDorsten
Journal:  Am J Obstet Gynecol       Date:  2014-06-28       Impact factor: 8.661

Review 6.  Use of labour induction and risk of cesarean delivery: a systematic review and meta-analysis.

Authors:  Ekaterina Mishanina; Ewelina Rogozinska; Tej Thatthi; Rehan Uddin-Khan; Khalid S Khan; Catherine Meads
Journal:  CMAJ       Date:  2014-04-28       Impact factor: 8.262

7.  Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria.

Authors:  H Lehnen; N Mosblech; T Reineke; A Puchooa; I Menke-Möllers; U Zechner; U Gembruch
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-05       Impact factor: 2.915

8.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

9.  10-Year cardiovascular event risks for women who experienced hypertensive disorders in late pregnancy: the HyRAS study.

Authors:  Wietske Hermes; Arie Franx; Maria G van Pampus; Kitty W Bloemenkamp; Joris A van der Post; Martina Porath; Gabrielle Ponjee; Jouke T Tamsma; Ben W Mol; Christianne J de Groot
Journal:  BMC Pregnancy Childbirth       Date:  2010-06-01       Impact factor: 3.007

10.  Diagnosis and management of pre-eclampsia: an update.

Authors:  Judi A Turner
Journal:  Int J Womens Health       Date:  2010-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.